Neuromodulation using the optimal rTMS stimulation frequency for Major Depressive Disorder (MDD)

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
University of Pennsylvania, Philadelphia, PA
Major Depressive Disorder (MDD)+5 More
Transcranial Magnetic Stimulation - Device
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

Generating personalized brain signatures of negative emotion along with personalized brain stimulation protocols to disrupt these patterns. We plan to use fMRI and muscle activity data to determine negative affect maps for each participant. We will then try a variety of patterned repetitive transcranial magnetic stimulation sequences while recording fMRI which will be the basis of two sessions of 3-day individualized brain stimulation designed to reduce negative affect.

Eligible Conditions

  • Major Depressive Disorder (MDD)
  • Anxiety
  • Rumination Disorders

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: Up to 4 weeks

Up to 4 weeks
Change in ruminative response scale (RRS) score after using the optimal rTMS stimulation frequency vs the least optimal rTMS stimulation frequency

Trial Safety

Safety Progress

1 of 3

Trial Design

2 Treatment Groups

Neuromodulation using the least optimal rTMS stimulation frequency
1 of 2
Neuromodulation using the optimal rTMS stimulation frequency
1 of 2
Active Control
Experimental Treatment

40 Total Participants · 2 Treatment Groups

Primary Treatment: Neuromodulation using the optimal rTMS stimulation frequency · No Placebo Group · N/A

Neuromodulation using the optimal rTMS stimulation frequency
Device
Experimental Group · 1 Intervention: Transcranial Magnetic Stimulation · Intervention Types: Device
Neuromodulation using the least optimal rTMS stimulation frequency
Device
ActiveComparator Group · 1 Intervention: Transcranial Magnetic Stimulation · Intervention Types: Device
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Transcranial Magnetic Stimulation
2011
Completed Phase 4
~580

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: up to 4 weeks

Trial Background

Prof. Desmond Oathes, Assistant Professor of Psychiatry
Principal Investigator
University of Pennsylvania
Closest Location: University of Pennsylvania · Philadelphia, PA
Photo of Hospital of the University of Pennsylvania  1Photo of Hospital of the University of Pennsylvania  2Photo of University of Pennsylvania  3
2011First Recorded Clinical Trial
17 TrialsResearching Major Depressive Disorder (MDD)
1048 CompletedClinical Trials

Eligibility Criteria

Age 18+ · All Participants · 6 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
Patient Health Questionnaire (PHQ-9 score) > or = 10.
You are able to understand instructions given in English.
You are between the ages of 18 and 65 years old.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.